The role of M1 to M2 macrophage polarization in the etiology of idiopathic gastroparesis: GWAS perspective - Smieszek, Sandra P.; Carlin, Jesse L.; Xiao, Changfu; Polymeropoulos, Christos M.; Birznieks, Gunther; Polymeropoulos, Mihael H. (medRxiv, 2022)
Gastroparesis is a serious medical condition characterized by delayed gastric emptying and symptoms of nausea, vomiting, bloating, fullness after meals, and abdominal pain. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system are likely central to the pathogenesis of gastroparesis. Thus far, little is known about the underlying genetic risk factors for gastroparesis. To ascertain these genetic risk factors for gastroparesis we conducted the first large whole-genome sequencing genome-wide association study (GWAS) analysis of gastroparesis patients.The GWAS focused on idiopathic and diabetic gastroparesis cases as compared to matched controls as well as compared idiopathic versus diabetic cases. Amongst the top variants, we report a novel genetic risk variant for idiopathic gastroparesis - genetic association of the Solute Carrier Family 15 (SLC15) locus. This signal is driven by multiple variants with top missense variant SLC15A4:NM145648:exon2:c.T716C:p.V239A, rs33990080. SLC15A4 was shown to mediate M1-prone metabolic shifts in macrophages and guards immune cells from metabolic stress. The risk variant carriers have a significantly higher nausea score at baseline. We also delineated a number of statistically significant loci including novel ones as well as previously known loci such as HLA-DQB1 - rs9273363, variant associated with Type 1 diabetes..The GWAS picture that is emerging implicates the role of the machinery of M1 to M2 macrophage polarization in the etiology of idiopathic gastroparesis. We suggest that macrophage polarization fate could lead to the destruction of the interstitial cells of Cajal which effectively leads to abnormal gastric emptying.Competing Interest StatementThe authors are employees of Vanda Pharmaceuticals Inc.Funding StatementThis study was funded by Vanda Pharmaceuticals Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra IRB Pro00032689I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesupon request